A phenomenon of the prostate gland, which is also shared by hair follicles, is that it is little influenced by @entity251 (T) for androgenic stimulation, but instead by its metabolite @entity586 ( @entity587 ). By blocking the conversion of T to @entity587 , the circulating level of @entity587 is reduced by 80%, the size of the prostate gland is reduced by about 20% and the level of @entity1486 (PSA) by about 50%. Treatment of @entity1 with obstructive @entity1067 ( @entity1067 ) with the drug @entity585 leads to a moderately improved urinary flow, symptomatic improvement and halts the natural progress of the disease. Since @entity587 potentiates the effect of @entity251 on erectile function, the side-effects are impotence in 3% of @entity1 , decreased ejaculatory volume, and gynaecomastia in 0.4% of @entity1 . The drug could be regarded as a safe way to treat moderately symptomatic @entity1067 . The efficacy of the drug is long-lasting (more than 7 years). It has also been tried in @entity263 , but is less effective. It reduces PSA levels by 50% and, in combination therapy, therefore, PSA levels remain low for longer when @entity585 is added. An important finding is the efficacy of @entity585 treatment in haematuria from @entity1067 . The drug interacts with vascular endothelium growth factor and efficiently prevents new @entity548 . It could be regarded as a first-line therapy for this type of haematuria. @entity585 can also be used to stop male baldness. It seems particularly effective in @entity1 aged 20-40 years; 85% of @entity1 stopped losing hair when given @entity585 . When the treatment was stopped hair loss continued, thus therapy may have to be "lifelong".

@entity585 in the treatment of @entity1067 : an update. New indications for XXXX therapy.

@entity1 :: ('9606', 'Species') :: ['patients', 'men'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity586 :: ('MESH:D013196', 'Chemical') :: ['5alpha-dihydrotestosterone'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity585 :: ('MESH:D018120', 'Chemical') :: ['Finasteride'] @entity1067 :: ('MESH:D011470', 'Disease') :: ['BPH', 'benign prostatic hypertrophy'] @entity587 :: ('CHEBI:16330', 'Chemical') :: ['DHT'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']
@entity585 :: (MESH:D018120,Chemical) :: ['finasteride']
